Sanny Chan
Allergy & Immunology · Santa Monica, CANPI 1043449788
Payments from drug & device makers
Across 549 payments — averaging $100.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$42K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi$1K
- GSK$1K
- Amgen$880
- plus $7K from 30 others
What the payments were for
- Consulting fees$871%
- Speaking & faculty fees$3502%
- Food & beverage$14,79697%
- Education$861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 83 | $41,768 |
| AstraZeneca | 69 | $2,427 |
| Regeneron Healthcare Solutions, Inc. | 33 | $1,281 |
| Sanofi | 47 | $1,220 |
| GSK | 44 | $1,187 |
| Amgen | 31 | $880 |
| Johnson & Johnson | 14 | $823 |
| Biocryst US Sales Co., LLC | 38 | $811 |
| Novartis | 34 | $714 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $674 |
| Octapharma USA, Inc. | 17 | $456 |
| Pfizer | 18 | $429 |
| Genentech USA, Inc. | 15 | $361 |
| Aimmune Therapeutics, Inc. | 2 | $350 |
| Optinose US, Inc. | 15 | $275 |
| Pharming Healthcare, Inc. | 4 | $272 |
| Kaleo, Inc. | 8 | $212 |
| Ionis Pharmaceuticals, Inc. | 5 | $129 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $127 |
| AbbVie | 1 | $125 |
| Blueprint Medicines Corporation | 4 | $120 |
| ADMA Biomanufacturing LLC | 5 | $111 |
| Bio Products Laboratory USA, Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 3 | $77 |
| Galderma Laboratories, L.p. | 3 | $70 |
| Cycle Pharmaceuticals Inc | 3 | $65 |
| Alk-abello, Inc | 3 | $56 |
| Boehringer Ingelheim | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Biocryst Pharmaceuticals, Inc. | 1 | $28 |
| Grifols USA, LLC | 1 | $26 |
| Incyte Corporation | 1 | $25 |
| Mylan Specialty L.p. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Sobi, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,318 in reported general payments places this provider in the 85th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 13 | $535,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $59,834 |
| XolairOmalizumab | 20 | $54,116 |
| Dupixent SyringeDupilumab | 12 | $43,902 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $11,016 |
| Epinephrine | 37 | $8,498 |
| Cromolyn Sodium | 18 | $8,134 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,304 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $6,070 |
| Azelastine Hcl | 93 | $3,729 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $3,436 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 34 | $2,911 |
| Ipratropium Bromide | 74 | $2,556 |
| Montelukast Sodium | 166 | $1,568 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $811 | $535,33713 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,187 | $76,92086 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $8,49837 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $65 | $8,13418 claims |
| AstraZenecaSymbicort | $2,427 | $6,30417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Santa Monica
- Raffi TachdjianSanta Monica$4.2M
- Lorraine AndersonSanta Monica$55K
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Vinay MehtaLaguna Niguel$3.3M
- Alan GoldsobelSan Jose$3.3M
- Steven WeinsteinHuntington Beach$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.